Serbian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Страна 1 од 318 резултати
N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has
Complementary Intervention for COVID-19
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Since last December 2019, a syndrome of severe pneumonia associated with the coronavirus disease 2019 (COVID-19) emerged in Wuhan, Hubei Province, China. It is highly contagious and rapidly spread to many other parts of China and almost all countries all over the world, representing one of the most
Therapeutic Plasma Exchange (TPE) for Covid-19 Cytokine Release Storm (CRS)
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
PROTOCOL SUMMARY:
Long title: Proposed use of TPE (therapeutic plasma exchange), to Limit Coronavirus Associated Complications: An Open label, Phase 2 Study
Clinical Phase: Two arms, Phase 2 Open Label
Conducted by: Department of Pulmonology and Critical Care; Pak Emirates Military Hospital.
Sample
Decision Support System Algorithm for COVID-19 Diagnosis
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Coronavirus disease 2019 (COVID-19) consists mainly of a respiratory infection that spans from a mild involvement of the upper respiratory tract to severe pneumonia leading to respiratory distress, shock, and death. Fever, cough, and dyspnea/tachypnea, together with myalgia and fatigue, have been
Obesity Surgery During 2020 Italian Pandemic
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Background Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) . The disease was first identified in December 2019 in Wuhan, the capital of China's Hubei province, and has since spread globally, resulting in the ongoing
Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Clinical Design. Eligible healthcare workers (HCW) or first responders in the greater New Orleans area (n=60) meeting eligibility criteria will be enrolled into a 12 month study by the Louisiana State University Health Sciences Center Clinical & Translational Research Center (LSUHSC CTRC) clinical
Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Evaluation of Clinical Characteristics and Outcome of COVID19 Pneumonia in Assiut University Hospital
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China.
Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
The novel coronavirus (SARS-CoV-2), is a single-stranded RNA coronavirus. The virus was first isolated from patients presented with pneumonia in Wuhan in December 2019.Sequences of the Wuhan betacoronavirus show similarities to betacoronaviruses found in bats, sharing a common ancestor with the 2003
Investigation of Safety and Efficacy of CARDIO Softgels in Former Smokers and Asthma Patients With COVID-19 Infection
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
SARS-CoV-2, a plus-sense single-stranded RNA virus, is the etiologic agent of COVID-19. After an incubation period, which typically lasts for 5-6 days, COVID-19 patients present with a mild illness that lasts for a few days. Common symptoms are reminiscent of the flu, and include fever, dry cough
Physiotherapy as a Complimentary Treatment in Reducing Viral-Load, Complications, Death, Expedite Discharge and Improve Quality of Life, Exercise Endurance and Capacity in Stroke Survivors With CoViD-19: A Clinical-Controlled Study
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Introduction Coronavirus disease 2019 (CoViD-19) is a new pathogen that is highly contagious, can spread quickly, and it is capable of causing enormous health, economic and societal impacts in any setting (WHO-China joint mission on CoViD-19). Although COVID 19 belongs to coronavirinae sub-family
Efficacy and Safety of Sirolimus in COVID-19 Infection
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
In early December 2019, several pneumonia cases of unknown origin were observed in Wuhan (China). A novel enveloped RNA β coronavirus was isolated and named severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2). The new virus rapidly spread across China and worldwide. On March 11th 2020, the
Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Pragmatic, double-blind, placebo-controlled randomized parallel-group, two-arm clinical trial (with allocation ratio 1:1), evaluating hydroxychloroquine (800 mg at 1st day, and 400 mg from day 2 to 7) for prevention of hospitalization and respiratory complications in non-hospitalized confirmed or
Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
In early December 2019, several pneumonia cases of unknown origin were observed in Wuhan (China). A novel enveloped RNA β coronavirus was isolated and named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The new virus rapidly spread across China and worldwide. On March 11th 2020, the
Најкомплетнија база лековитог биља подржана науком
- Ради на 55 језика
- Биљни лекови потпомогнути науком
- Препознавање биљака по слици
- Интерактивна ГПС мапа - означите биље на локацији (ускоро)
- Читајте научне публикације повезане са вашом претрагом
- Претражите лековито биље по њиховим ефектима
- Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима
Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима
